Rota P A, De B K, Shaw M W, Black R A, Gamble W C, Kendal A P
Division of Viral and Rickettsial Diseases, Centers for Disease Control, Atlanta, GA 30333.
Virus Res. 1990 Apr;16(1):83-93. doi: 10.1016/0168-1702(90)90045-d.
The protective efficacy of influenza hemagglutinin expressed from recombinant vaccinia virus was compared with that induced by inactivated or infectious influenza vaccines. Intraperitoneal and intranasal routes of vaccination were compared. All the vaccines except the intranasally administered, inactivated vaccine induced detectable levels of neutralizing and hemagglutination-inhibiting antibodies in the serum of mice at 28 days postvaccination. Immunization with any of the intranasally administered vaccines reduced the amount of influenza virus nucleoprotein antigen in lungs after challenge with a homologous, mouse-adapted strain of influenza virus. Intraperitoneally administered vaccines failed to provide such protection. These results indicated that the route of vaccine administration may be the most critical factor for inducing protective immunity. The results also showed that in this mouse model a recombinant DNA-based vaccine could provide protection equivalent to that provided by conventional attenuated and inactivated influenza vaccines.
将重组痘苗病毒表达的流感血凝素的保护效力与灭活或感染性流感疫苗诱导的保护效力进行了比较。比较了腹腔内和鼻内接种途径。除鼻内接种的灭活疫苗外，所有疫苗在接种后28天均能在小鼠血清中诱导出可检测水平的中和抗体和血凝抑制抗体。用任何一种鼻内接种疫苗免疫后，在用同源的、适应小鼠的流感病毒株攻击后，肺部流感病毒核蛋白抗原的量减少。腹腔内接种疫苗未能提供这种保护。这些结果表明，疫苗接种途径可能是诱导保护性免疫的最关键因素。结果还表明，在该小鼠模型中，基于重组DNA的疫苗可提供与传统减毒和灭活流感疫苗相当的保护。
